Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$233,538.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK082025-01A1
Award Id:
93697
Agency Tracking Number:
DK082025
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NOVELMED THERAPEUTICS, INC., 2265 ENTERPRISE PKWY, TWINSBURG, OH, 44087
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
190155171
Principal Investigator:
REKHA BANSAL
(440) 477-9874
REKHA@NOVELMED.COM
Business Contact:
REKHA BANSAL
() -
rekha@novelmed.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Approximately 400,000 people with end stage renal disease undergo hemodialysis in the United States each year. During the hemodialysis procedure, the patient's blood circulates through the dialyzer and back to the patie nt. As a result, the patient's blood encounters the artificial surfaces of the dialyzer and the tubings that connect the patient to the dialyzer. As a result, the complement alternative pathway is activated, causing generation of substantial amounts of C3a and C5a anaphylatoxins. These anaphylatoxins activate neutrophils, monocytes, and platelets, and trigger the inflammatory cascade. NovelMed has developed a monoclonal antibody, which prevents a) C3a, C5a, C5b-9, production, b) neutrophils, monocytes, and platelet activation, and c) TNF-alpha production. In this application, we propose testing the feasibility of using Bikaciomab to prevent the exacerbated inflammatory response that occurs when blood circulates through the dialyzer and associated tubing. Bas ed on current preliminary data, it is clear that Bikaciomab is a novel, target specific, and highly potent drug candidate that would prevent inflammation during dialysis. We believe that such drugs would increase the quality of life for hemodialysis patien ts. PUBLIC HEALTH RELEVANCE: Approximately 350,000 people with end stage renal disease undergo hemodialysis in the United States each year. In this already compromised patient population, virtually every patient suffers side effects from this hemodialys is procedure at one time or another due to activation of the alternate complement pathway (AP). Bikaciomab blocks the alternative pathway in blood circulating through an extra corporeal blood circulation model of hemodialysis. It is hoped that such an appr oach will eventually result in improved morbidity and mortality in the patients suffering from End Stage Kidney Failure. Public Health Relevance Statement Page 7

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government